Clinical Trial

Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 5, 2024 (before its estimated October 19, 2025 completion). Its status may not reflect the trial's current state.
Summary
To explore the efficacy and safety of prolonged low-dose decitabine (10 days of 6mg/m2) plus venetoclax (3 weeks/cycle) regimen in primary diagnosed elderly or frail AML/ high-risk MDS.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-09-18.
Status change: Not Yet Recruiting → Recruiting 2024-03-02
Trial Details
NCT Number NCT06046313
Lead Sponsor First Affiliated Hospital of Zhejiang University
Conditions Acute Myeloid Leukemia, Myelodysplastic Syndromes
Enrollment 120 participants
Start Date 2023-10-19
Primary Completion 2025-10-19 (estimated)
Study Completion 2026-10-19 (estimated)
Updated on ClinicalTrials.gov 2024-03-05